Neurogene Raises $68.5 Million in Series A Financing to Advance Multiple Programs in Devastating Neurological Diseases

Proceeds support a product pipeline with multiple AAV-based gene
therapies with disease-modifying potential and creation of a
company-owned AAV manufacturing facility

NEW YORK–(BUSINESS WIRE)–Neurogene,
Inc
., a company founded with a mission to bring life-changing
medicines to patients and families affected by rare neurological
diseases, today announced a $68.5 million Series A financing. Investors
included Samsara BioCapital, EcorR1 Capital, Cormorant Asset Management,
Redmile Group and an undisclosed leading healthcare investment fund.

Neurogene’s mission is to improve patient outcomes by advancing genetic
medicines for many neurological disorders for which the company may make
a tangible, life-altering difference. Neurogene partners with leading
academic researchers, patient advocacy organizations and caregivers to
bring therapies that address the underlying genetic cause of a broad
spectrum of neurological diseases where no effective treatment options
exist today.

“Neurogene is reimagining the future for patients with rare neurological
diseases and their families,” said Rachel McMinn, Ph.D., Founder and
Chief Executive Officer. “Through partnerships and our own internal
expertise, we are advancing our gene therapy programs for rare
neurological disorders. The vast majority of rare diseases remain
unaddressed, and our goal is to enable a better future for patients with
these diseases.”

With the funding announced today, Neurogene will advance multiple gene
therapy programs into IND-enabling studies and clinical trials for
patients with rare neurological diseases, invest in novel technologies
for indications not addressed by traditional gene therapy approaches and
establish a viral vector manufacturing facility.

About Neurogene, Inc.
Neurogene was founded to bring
life-changing medicines to patients and families affected by rare
neurological disorders. We partner with leading academic researchers,
patient advocacy organizations and caregivers to bring therapies to
patients that address the underlying genetic cause of a broad spectrum
of neurological diseases where no effective treatment options exist
today. Our lead programs use AAV-based gene therapy technology to
deliver a normal gene to patients with a dysfunctional gene. Neurogene
is also investing in novel technologies to develop treatments for
diseases not well served by gene therapy. For more information, visit www.neurogene.com.

Contacts

Sara Green, Ten Bridge Communications
[email protected]
617-233-1714

error: Content is protected !!